BioSpace News Archive

NurExone Biologic Inc. today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023.

TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, announced that it is developing a streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000.

Canada’s largest pharmaceutical company, Apotex Inc. and Searchlight Pharma Inc. (“Searchlight”), one of Canada’s fastest growing companies, announced today that they have reached an agreement whereby Apotex will acquire Searchlight.

The treadmill exercise test is an important tool for diagnosing coronary artery disease, but limited by time spent for the manual interpretation of a dozen charts and the challenges in identifying minor deviations.

Genprex, Inc. today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing the Company’s non-viral Oncoprex® Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (NSCLC) in a humanized mouse model.

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.

Aditxt, Inc. announced that it has entered into a definitive arrangement agreement to acquire Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures.

ADARx Pharmaceuticals, Inc. today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).

Jaguar Health, Inc. today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International.

Spectral Medical Inc. announced that Anthony Bihl III, Spectral’s Chairman, will be retiring from the Board at Spectral’s upcoming Shareholder Meeting in June 2024.